Sign in

The Lancet Neurology

@thelancetneuro.bsky.social
1.4K followers 53 following 310 posts

The Lancet Neurology is the leading journal in clinical neurology. We publish articles and reviews that advocate change in, or illuminate, clinical practice. 🌐 www.thelancet.com/journals/laneur/h…

PostsRepliesMedia
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 08/10/2026
🆕 Out now: The Lancet Regional Health – Eastern Mediterranean’s inaugural issue. #goldopenaccess “The scale of the challenges the region has faced this past year can be hard to absorb. It is in this context that this journal takes shape.” Explore the new issue: spkl.io/633277VQx7
Cover of The Lancet Regional Health – Eastern Mediterranean’s inaugural issue. Artwork by Tasneem El Meshad.
044
The Lancet Neurology @thelancetneuro.bsky.social · 08/10/2026
Now online @thelancet.com: a new Seminar on migraine, covering epidemiology, clinical presentation, diagnosis, and outcomes, pathophysiology, and treatment www.thelancet.com/journals/lan...
thelancet.com
Migraine
Migraine is a chronic neurovascular disorder characterised by recurrent attacks of moderate-to-severe head pain, accompanied by transient but disabling symptoms such as aura, nausea, vomiting, phonoph...
173
Reposted by The Lancet Neurology
The Lancet Obstetrics, Gynaecology, & Women’s Health @lancetobgyn-wh.bsky.social · 08/10/2026
New Online, a Review by Connar Westgate & colleagues of idiopathic intracranial hypertension, a disorder that primarily affects young women with obesity. Read more about this increasingly common disorder, and the implications for reproductive health and pregnancy: www.thelancet.com/journals/lan...
thelancet.com
Idiopathic intracranial hypertension in women: implications for reproductive health and pregnancy
Idiopathic intracranial hypertension is a condition characterised by a potentially sight-threatening increase in intracranial pressure with no known cause, and it is strongly associated with obesity i...
033
Reposted by The Lancet Neurology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 07/10/2026
📈Read one of our editor picks for September Tao et coll from TRACK-FA neuroimaging consortium evaluated the potential of geometric brain signatures for characterising hereditary ataxia and predicting functional brain organisation. www.thelancet.com/journals/lan... #neurosky
thelancet.com
Geometric brain signatures for characterising hereditary ataxia and predicting functional brain organisation: a retrospective multicohort study
The exploratory geometry-driven deep learning approach used in this study proposes to describe brain changes across multiple scales by integrating structural and functional information and predicts br...
031
Reposted by The Lancet Neurology
The Lancet Rheumatology @thelancetrheum.bsky.social · 06/10/2026
NEW—CAR T cells for autoimmune diseases: 2026 update of the EBMT–ISCT–JACIE practice harmonisation and consensus recommendations bit.ly/4rMqjLy #MedSky #RheumSky #NeuroSky #HaemSky
001
Reposted by The Lancet Neurology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 06/10/2026
📈Read one of our editor picks for September Gatto & coll from Mayo clinic investigated the origins of off-target tau-PET binding in frontotemporal lobar degeneration, esp the contributions of TDP-43 and annexin A11. 🧠 www.thelancet.com/journals/lan... #neurosky
thelancet.com
Investigation of TDP-43 and annexin A11 contributions to off-target tau-PET binding in frontotemporal lobar degeneration: a retrospective, observational study
Flortaucipir uptake in FTLD-TDP, particularly type C, could reflect off-target binding to phosphorylated TDP-43 and ANXA11 aggregates in limbic regions rather than tau pathology alone; consequently, t...
111
The Lancet Neurology @thelancetneuro.bsky.social · 06/10/2026
Our October issue In Context section includes a historical Focal Point on electrophysiology, an Insight on third sector organisations in neuropalliative care, a book review on ancient brains in the modern world, and more! www.thelancet.com/journals/lan...
thelancet.com
The Lancet Neurology, October 2026, Volume 25, Issue 10, Pages 873-964, e14
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
010
The Lancet Neurology @thelancetneuro.bsky.social · 05/10/2026
ICYMI: a Series of three papers explores how clinical practice for Alzheimer's Disease and related disorders might evolve over the next 5–10 years, particularly related to fluid biomarkers, neuroimaging, and clinical pathways for cognitively unimpaired individuals www.thelancet.com/journals/lan...
thelancet.com
The Lancet Neurology, October 2026, Volume 25, Issue 10, Pages 873-964, e14
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
110
The Lancet Neurology @thelancetneuro.bsky.social · 02/10/2026
In our October issue correspondence section: letters on brain capital versus brain capitalism, traumatic brain injury in China, and a new era for neuroimmunology in Africa www.thelancet.com/journals/lan...
thelancet.com
The Lancet Neurology, October 2026, Volume 25, Issue 10, Pages 873-964, e14
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
010
The Lancet Neurology @thelancetneuro.bsky.social · 01/10/2026
Online first: changes in Alzheimer's disease plasma biomarkers in patients receiving lecanemab www.thelancet.com/journals/lan...
thelancet.com
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study
Lecanemab treatment was associated with dynamic, multidirectional changes across plasma biomarkers of Alzheimer's disease pathology, with partial normalisation of amyloid and tau biomarkers alongside ...
110
The Lancet Neurology @thelancetneuro.bsky.social · 29/09/2026
Now online - the September issue of @lancetimaging.bsky.social includes research papers on brain tumours, frontotemporal lobar degeneration, and hereditary ataxia
020
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 27/09/2026
Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows. Find out more in The Lancet: spkl.io/633297TFyz #EANO2026 @eanoassociation.bsky.social
Kaplan–Meier estimates of disease-free survival by treatment group in the intention-to-treat population. Median follow-up was 64 months (IQR 50–75). HR=hazard ratio. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
095
The Lancet Neurology @thelancetneuro.bsky.social · 24/09/2026
Out now, the September issue of @eclinicalmed.bsky.social includes research papers on acute ischaemic stroke, cerebral small vessel disease, degenerative cervical myelopathy, infection-triggered encephalopathy, and more!
010
The Lancet Neurology @thelancetneuro.bsky.social · 23/09/2026
Prevalence of unruptured intracranial aneurysms - overall, in individuals with risk factors, in subgroups with comorbid diseases, time trends, and regional differences - assessed in a systematic review and meta-analysis, now in our October issue www.thelancet.com/journals/lan...
thelancet.com
Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis
Prevalence of UIA is increasing, particularly over the past two decades. This increase is only in part explained by improved detection of small UIAs and an ageing population, and other factors—such as...
110
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 21/09/2026
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, find the EVOKE and EVOKE+ trials. Find out more ▶️ spkl.io/633297Tzif #WorldAlzheimersDay
Research in context panel for Lancet paper "Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials". Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
055
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 21/09/2026
The field of Alzheimer’s disease has seen transformative advances that are beginning to reshape clinical practice. On #WorldAlzheimersDay, read a Seminar summarising the progress made and highlight the unmet needs and priorities for future research: spkl.io/633297Tz97
(A) MRI features of small vessel disease in an 86-year-old man with poorly controlled chronic hypertension. FLAIR shows severe periventricular white matter hyperintensities and lacunar strokes in basal ganglia (arrows). SWI shows multiple microbleeds in basal ganglia typical of hypertensive microangiopathy (arrows). (B) MRI features of cerebral amyloid angiopathy in a 71-year-old man with mild cognitive impairment and a positive [18F]-florbetaben amyloid PET. SWI revealed up to 12 microbleeds and three areas of focal cortical superficial siderosis (arrows), one in the right frontal lobe. FLAIR showed the typical multispot pattern of white matter hyperintensities in centri semiovale. T2 showed enlarged perivascular spaces in centri semiovale. FLAIR=fluid-attenuated inversion recovery. SWI=susceptibility weighted imaging.
093
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 19/09/2026
ICYMI - A Series in @thelancetneuro.bsky.social explores how Alzheimer's disease clinical practice might evolve over the next 5–10 years, focusing on: ➡️ fluid biomarkers ➡️ neuroimaging ➡️ clinical pathways for cognitively unimpaired individuals Read now: spkl.io/633277rPsR #WorldAlzheimersMonth
Promotional card for The Lancet Neurology Series on Future Directions of Alzheimer's Disease and Related Disorders. Image on card: A gloved hand holds up a sample tube in front of a computer screen displaying brain scans. There is a rack of sample tubes in the foreground. Copyright: Tek Images/Science Photo Library.
042
The Lancet Neurology @thelancetneuro.bsky.social · 17/09/2026
In our October issue: results of HIMALAYA, an international phase 2 trial of the oral RIPK1 inhibitor SAR443820 for amyotrophic lateral sclerosis www.thelancet.com/journals/lan...
thelancet.com
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
SAR443820 did not show clinical benefit and was associated with higher hepatic enzyme increase, indicating that further clinical development of SAR443820 in ALS is not warranted.
132
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 16/09/2026
A new AI tool could help doctors avoid unnecessary contrast-dye injections for some brain tumour patients, according to a study in @lancetimaging.bsky.social Explore the research 👉 tinyurl.com/2uufu6ur
tinyurl.com
Predicting brain tumour enhancement from non-contrast MRI with artificial intelligence: a multicohort, retrospective, diagnostic accuracy study
Deep learning can identify contrast-enhancing brain tumours from non-contrast MRI. These models show promise as a triage or decision-support aid—for example, flagging studies in which post-contrast en...
1157
The Lancet Neurology @thelancetneuro.bsky.social · 15/09/2026
Vibrance-1, a randomised trial of the oral orexin 2 receptor agonist alixorexton for narcolepsy type 1, now in our October issue: www.thelancet.com/journals/lan...
thelancet.com
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
In this phase 2 trial, once-daily oral alixorexton provided clinically meaningful improvements at 6 weeks for participants with narcolepsy type 1, including in wakefulness, excessive daytime sleepines...
142
The Lancet Neurology @thelancetneuro.bsky.social · 11/09/2026
New online! Plasma phosphorylated tau 217 (p-tau217) concentrations, APOE genotype, and timing of cognitive impairment, in a pooled analysis of participant-level data from seven diverse prospective cohorts of older adults in Canada, Dominican Republic, and USA www.thelancet.com/journals/lan...
thelancet.com
Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies
Plasma p-tau217 concentrations, considered together with APOE genotype, might help stratify risk and estimate the timing of future cognitive impairment in asymptomatic individuals who are at increased...
031
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 10/09/2026
In @thelancetneuro.bsky.social, a new Series explores how Alzheimer's disease clinical practice might evolve over the next 5–10 years, focusing on: ➡️ fluid biomarkers ➡️ neuroimaging ➡️ clinical pathways for cognitively unimpaired individuals Read now: spkl.io/633207R5si
Promotional card for The Lancet Neurology Series on Future Directions of Alzheimer's Disease and Related Disorders. Image on card: A gloved hand holds up a sample tube in front of a computer screen displaying brain scans. There is a rack of sample tubes in the foreground. Copyright: Tek Images/Science Photo Library.
085
Reposted by The Lancet Neurology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 10/09/2026
Our first editorial, in our August issue, presents our vision and hopes for the new journal. We are all looking forward working with researchers & clinicians to advance imaging and improve health. Read bit.ly/3VmfOSY
012
The Lancet Neurology @thelancetneuro.bsky.social · 10/09/2026
NEW ISSUE! Read the latest content on narcolepsy, amyotrophic lateral sclerosis, unruptured intracranial aneurysms, future directions in Alzheimer's disease, and more, in our October 2026 issue: www.thelancet.com/issue/S1474-...
The cover of the October 2026 issue of The Lancet Neurology. Cover image shows three pairs of figures, one in the centre foreground and two in the background, all standing on concentric circles, against a purple background. The central figures are a woman with a walking stick being assisted by a health-care professional, related to the Insight paper on neuropalliative care. Text at the bottom of the cover highlights Articles on amyotrophic lateral sclerosis and unruptured intracranial aneurysms and Series papers on future directions in Alzheimer's disease. Cover image by Harry Tennant.
041
The Lancet Neurology @thelancetneuro.bsky.social · 09/09/2026
ICYMI: our September issue editorial calls for epilepsy care to extend well beyond seizure control www.thelancet.com/journals/lan...
thelancet.com
Epilepsy care must look beyond seizure control
More than 50 million people live with active epilepsy worldwide, making it one of the most common neurological conditions across the lifespan. More than 80% of this burden falls on poor regions, where...
030
The Lancet Neurology @thelancetneuro.bsky.social · 08/09/2026
ICYMI: the RECAP-ICH meta-analysis of long-term blood pressure-lowering for secondary prevention after spontaneous intracerebral haemorrhage www.thelancet.com/journals/lan...
thelancet.com
Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis
Intensive blood pressure-lowering treatment after spontaneous intracerebral haemorrhage reduces recurrent stroke, mainly by preventing recurrent haemorrhage, without evidence of excess serious adverse...
030
The Lancet Neurology @thelancetneuro.bsky.social · 07/09/2026
The latest issue of @lancetrh-europe.bsky.social also includes Articles on a Parkinson's disease toolkit, intracranial pressure monitoring in severe bacterial meningitis, the burden of dementia in Europe, and genome sequencing in cerebral palsy
083
The Lancet Neurology @thelancetneuro.bsky.social · 07/09/2026
ICYMI in our September issue: a Personal View on cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities, including potential mechanisms, effects on cognition, and cardiovascular safety www.thelancet.com/journals/lan...
thelancet.com
Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities
Bradycardia due to cardiac conduction abnormalities is prevalent in patients with dementia with Lewy bodies possibly due to autonomic dysfunction and neurodegeneration. Cholinesterase inhibitors remai...
163
The Lancet Neurology @thelancetneuro.bsky.social · 04/09/2026
ICYMI: a new EURAP study investigates the risks of poor fetal growth in infants exposed prenatally to antiseizure medications, comparing monotherapy versus polytherapy, different monotherapies, and common antiseizure medication combinations www.thelancet.com/journals/lan...
thelancet.com
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
In addition to congenital malformations and neurodevelopmental effects, poor fetal growth should be regarded as an important adverse outcome of prenatal antiseizure medication exposure. Risk varies ac...
130
The Lancet Neurology @thelancetneuro.bsky.social · 03/09/2026
ICYMI: a Review in our September issue on management of chronic subdural haematoma (CSDH) covers diagnosis, recurrence, surgical strategies, middle meningeal artery embolisation (MMAE), pharmacotherapies, conservative management, and future directions www.thelancet.com/journals/lan...
thelancet.com
Advances in chronic subdural haematoma management: beyond the burr hole
Chronic subdural haematoma is associated with increased frailty, comorbidities including dementia, and a higher risk of mortality compared to age-matched controls, with incidence rising as populations...
021
The Lancet Neurology @thelancetneuro.bsky.social · 02/09/2026
New online! Prevalence of unruptured intracranial aneurysms - overall, in individuals with risk factors, in subgroups with comorbid diseases, time trends, and regional differences - assessed in a new systematic review and meta-analysis www.thelancet.com/journals/lan...
thelancet.com
Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis
Prevalence of UIA is increasing, particularly over the past two decades. This increase is only in part explained by improved detection of small UIAs and an ageing population, and other factors—such as...
110
Reposted by The Lancet Neurology
The Lancet Primary Care @lancetprimarycare.bsky.social · 01/09/2026
🆕 In their three-arm randomised controlled trial, Paul Little and colleagues investigated whether a #digitalintervention resulted in improvement in #cognitivehealth in older adults with #cognitiveimpairment at 12 months Read the full Article here ➡️ www.thelancet.com/journals/lan...
Research in context panel describing the evidence before this study, the added value of this study, and the implications of all the available evidence
021
The Lancet Neurology @thelancetneuro.bsky.social · 01/09/2026
Our September issue In Context section includes a Profile of Gisela Terwindt, an Insight on the molecular evolution of Parkinson's disease, book reviews on language and music, and more! www.thelancet.com/journals/lan...
thelancet.com
The Lancet Neurology, September 2026, Volume 25, Issue 9, Pages 789-872
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
020
The Lancet Neurology @thelancetneuro.bsky.social · 28/08/2026
For decades, vanishing white matter had no treatment, but might a blood-pressure pill offer hope? Find out more in our latest podcast: www.thelancet.com/audio-do/mar... Apple: podcasts.apple.com/gb/podcast/t... Spotify: open.spotify.com/show/0dY5qiz... Amazon: music.amazon.co.uk/podcasts/986...
thelancet.com
Marjo van der Knaap on vanishing white matter
For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurolog...
021
Reposted by The Lancet Neurology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 27/08/2026
📢 We’ve published our first issue! Thank you to our authors and reviewers for their valuable contributions ✨ As a #goldopenaccess journal, our content is free to read by everyone, always. Read and download our inaugural issue here ➡️ bit.ly/4y6p9wt #MedSky #RadSky
Representative images of individuals with different NMN BBB scores. The left column shows contrast enhanced MRI brain scans and the right column shows the fusion of the MRI scans and PET scans of these same individuals.  The top row corresponds to an individual with a NMN BBB score of 2 as minor parts of PET-positive volume show contrast enhancement on MRI. The bottom row corresponds to an individual with a NMN BBB score of 5 as the PET positive volume shows complete contrast enhancement on MRI. 
Copyright: The authors, Nathalie Albert and colleagues. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
024
The Lancet Neurology @thelancetneuro.bsky.social · 27/08/2026
Now online: the Vibrance-1 randomised trial of alixorexton, an oral orexin 2 receptor agonist, for narcolepsy type 1 www.thelancet.com/journals/lan...
thelancet.com
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
In this phase 2 trial, once-daily oral alixorexton provided clinically meaningful improvements at 6 weeks for participants with narcolepsy type 1, including in wakefulness, excessive daytime sleepines...
120
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 22/08/2026
We're inviting submissions for the 2025 #WakleyPrize Essay Competition. ✍️ Explore this year's theme, put pen to paper, and submit your work today: spkl.io/633267zgsE
Promotional card for The Lancet's Wakley Prize Essay Competition. Text on card reads: The Wakley Prize Essay Competition: A call for submissions. Background image is of Thomas Wakley, who founded The Lancet in 1823.
055
The Lancet Neurology @thelancetneuro.bsky.social · 26/08/2026
Our September issue Correspondence section includes letters on neurorehabilitation, dementia with Lewy bodies, and brain health access for all: www.thelancet.com/journals/lan...
thelancet.com
The Lancet Neurology, September 2026, Volume 25, Issue 9, Pages 789-872
Explore the current issue of The Lancet Neurology, a monthly journal covering international issues relevant to neurologists worldwide
030
The Lancet Neurology @thelancetneuro.bsky.social · 25/08/2026
New online in @lancetrh-europe.bsky.social, a Review of neurogenic gastrointestinal, urinary, and sexual symptoms in multiple sclerosis, aiming to translate evidence into a pragmatic model of care tailored to the realities of European clinical practice www.thelancet.com/journals/lan...
thelancet.com
Neurogenic gastrointestinal, urinary, and sexual dysfunction in multiple sclerosis: a multidisciplinary framework for clinical practice
Neurogenic gastrointestinal, urinary, and sexual symptoms are highly prevalent in people with multiple sclerosis and substantially impair quality of life, daily functioning, and psychosocial well-bein...
011
The Lancet Neurology @thelancetneuro.bsky.social · 25/08/2026
Now in our September issue: the TEMPLE randomised trial of atogepant versus topiramate for prevention of migraine www.thelancet.com/journals/lan...
thelancet.com
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial
Atogepant 60 mg once daily showed better tolerability and efficacy across 24 weeks compared with topiramate. Although both topiramate and atogepant are established as effective oral migraine preventiv...
110
The Lancet Neurology @thelancetneuro.bsky.social · 24/08/2026
Out now, the new issue of @eclinicalmed.bsky.social includes papers on multiple sclerosis, unruptured intracranial aneurysms, Pompe disease, and more!
021
The Lancet Neurology @thelancetneuro.bsky.social · 24/08/2026
Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities: a Personal View in our September issue covers potential mechanisms and the effects of cholinesterase inhibitors on cognition and cardiovascular safety www.thelancet.com/journals/lan...
thelancet.com
Cholinesterase inhibitors in people with dementia with Lewy bodies and cardiac conduction abnormalities
Bradycardia due to cardiac conduction abnormalities is prevalent in patients with dementia with Lewy bodies possibly due to autonomic dysfunction and neurodegeneration. Cholinesterase inhibitors remai...
110
The Lancet Neurology @thelancetneuro.bsky.social · 20/08/2026
Risk of poor fetal growth in infants exposed prenatally to antiseizure medications: a new study from EURAP investigates the risks associated with monotherapy versus polytherapy, across different monotherapies, and across common antiseizure medication combinations www.thelancet.com/journals/lan...
thelancet.com
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
In addition to congenital malformations and neurodevelopmental effects, poor fetal growth should be regarded as an important adverse outcome of prenatal antiseizure medication exposure. Risk varies ac...
120
Reposted by The Lancet Neurology
The Lancet @thelancet.com · 19/08/2026
The Lancet's annual Highlights photography competition is open for submissions. 📷 We invite original photographs that capture the realities of health—from clinical care and community action to resilience, compassion, and hope. Find out more ➡️ spkl.io/6332378zCP
Promotional card for The Lancet's Highlights photography competition. Text on card reads: Highlights photography competition. A call for submissions. Image on card depicts a camera inside a hexagon outline.
064
The Lancet Neurology @thelancetneuro.bsky.social · 19/08/2026
Long-term blood pressure-lowering for secondary prevention after spontaneous intracerebral haemorrhage: results of the RECAP-ICH meta-analysis of randomised trials, reported in our September issue www.thelancet.com/journals/lan...
thelancet.com
Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis
Intensive blood pressure-lowering treatment after spontaneous intracerebral haemorrhage reduces recurrent stroke, mainly by preventing recurrent haemorrhage, without evidence of excess serious adverse...
010
The Lancet Neurology @thelancetneuro.bsky.social · 18/08/2026
Advances in chronic subdural haematoma management (CSDH): a new Review explores diagnosis and recurrence, surgical strategies, middle meningeal artery embolisation (MMAE), pharmacotherapies, and conservative management, and discusses future directions of care www.thelancet.com/journals/lan...
thelancet.com
Advances in chronic subdural haematoma management: beyond the burr hole
Chronic subdural haematoma is associated with increased frailty, comorbidities including dementia, and a higher risk of mortality compared to age-matched controls, with incidence rising as populations...
010
Reposted by The Lancet Neurology
The Lancet Medical Imaging & Theranostics @lancetimaging.bsky.social · 04/08/2026
🎉Really happy to share our first original research article, ahead of our inaugural issue of the journal. @guilhermepovala.bsky.social & colleagues from the HEAD study propose a PET–CT pipeline using low-dose CT to quantify tau PET without MRI. Read #openaccess bit.ly/45KxZUg #Alzheimers #MRI #PET
084
The Lancet Neurology @thelancetneuro.bsky.social · 17/08/2026
Guanabenz for vanishing white matter: results from a single-arm, phase 1/2 trial, in our September issue www.thelancet.com/journals/lan...
thelancet.com
Safety and efficacy of guanabenz in early-childhood onset vanishing white matter: primary analysis of a single-arm, phase 1/2 trial
Guanabenz treatment had an acceptable and manageable safety profile and, after the initial phase, was well tolerated in children with vanishing white matter. Treated patients with disease onset at age...
110
The Lancet Neurology @thelancetneuro.bsky.social · 13/08/2026
NEW ISSUE! Read the latest content on migraine, vanishing white matter, blood pressure-lowering after intracerebral haemorrhage, antiseizure medications in pregnancy, chronic subdural haematoma, dementia with Lewy bodies, and more, in our September 2026 issue: www.thelancet.com/journals/lan...
The cover of the September 2026 issue of The Lancet Neurology. Cover image shows a blue head in profile on a red background, with the brain represented as a tree losing its blossom. Text on the cover highlights Articles on vanishing white matter and antiseizure medications in pregnancy, and a Review on chronic subdural haematoma. Cover image by Harry Tennant.
010
The Lancet Neurology @thelancetneuro.bsky.social · 12/08/2026
The new issue of @ebiomedicine.bsky.social includes several research papers on biomarkers for Alzheimer’s disease and Parkinson's disease, including new analysis from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial www.thelancet.com/journals/ebi...
thelancet.com
eBioMedicine, August 2026, Volume 130
Read the current issue of EBioMedicine
010